>
Switch to:

PTC Therapeutics PS Ratio

: 5.48 (As of Today)
View and export this data going back to 2013. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, PTC Therapeutics's share price is $38.52. PTC Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2021 was $7.03. Hence, PTC Therapeutics's PS Ratio for today is 5.48.

The historical rank and industry rank for PTC Therapeutics's PS Ratio or its related term are showing as below:

NAS:PTCT' s PS Ratio Range Over the Past 10 Years
Min: 2.42   Med: 6.64   Max: 114.48
Current: 5.53

2.42
114.48

During the past 10 years, PTC Therapeutics's highest PS Ratio was 114.48. The lowest was 2.42. And the median was 6.64.

NAS:PTCT's PS Ratio is ranked higher than
72% of the 1012 Companies
in the Biotechnology industry.

( Industry Median: 14.25 vs. NAS:PTCT: 5.53 )

PTC Therapeutics's Revenue per Sharefor the three months ended in Sep. 2021 was $1.97. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2021 was $7.03.

During the past 12 months, the average Revenue per Share Growth Rate of PTC Therapeutics was 26.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 5.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 35.90% per year.

During the past 10 years, PTC Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 83.70% per year. The lowest was -42.40% per year. And the median was 5.10% per year.

Back to Basics: PS Ratio


PTC Therapeutics PS Ratio Historical Data

The historical data trend for PTC Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.49 3.36 6.04 9.21 10.58

PTC Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.42 10.58 7.50 6.21 5.29

Competitive Comparison

For the Biotechnology subindustry, PTC Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

PTC Therapeutics PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's PS Ratio falls into.



PTC Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

PTC Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=38.52/7.028
=5.48

PTC Therapeutics's Share Price of today is $38.52.
PTC Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


PTC Therapeutics  (NAS:PTCT) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


PTC Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

PTC Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Southwell David P director C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421
Jacobson Allan Steven director PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Peltz Stuart Walter director, officer: Chief Executive Officer PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Utter Christine Marie officer: SVP, Finance & CAO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Boulding Mark Elliott officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Hill Emily Luisa officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Svoronos Dawn director C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105
Pauwels Eric officer: Chief Business Officer 550 HILLS DRIVE BEDMINSTER NJ 07921
Klein Matthew B. officer: Chief Development Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Schmertzler Michael director 1300 VALLEY ROAD NEW CANAAN CT 06840
Souza Marcio officer: Chief Operating Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Almstead Neil Gregory officer: Chief Technical Ops Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Reeve Emma director C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232
Zeldis Jerome B director 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258

PTC Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)